Improving Outcomes in PD-L1+ Lung Cancer: Immunotherapy vs Combination with Chemotherapy

There are conflicting opinions over the superiority of immunotherapy vs combination therapy with chemo for the treatment of PD-L1-positive lung cancer. Attendees of this debate will hear about recent clinical trial data comparing immune checkpoint inhibitors (ICIs) to combination therapy with chemo, considering such factors as patient selection and overall survival. Experts will present the advantages and disadvantages of each therapeutic approach.